Euro
US Dollar
Product Description
CD110 Polyclonal Antibody |ELK Biotechnology Antibodies | is available at Gentaur for Next Week Delivery
Product Background: MPL proto-oncogene, thrombopoietin receptor(MPL) Homo sapiens In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important
Source: Rabbit
Application: WB,ELISA
Species Reactivity: Human
Recommended Dilution: N/A
Immunogenecity: Synthesized peptide derived from the Internal region of human CD110.
Speceficity: N/A
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Isotype: N/A
Observed Brand: 71 kDa
Cellular Localization: N/A
Alternative Names: MPL; TPOR; Thrombopoietin receptor; TPO-R; Myeloproliferative leukemia protein; Proto-oncogene c-Mpl; CD antigen CD110
